Author:
Murray Lindsey T.,Howell Timothy A.,Matza Louis S.,Eremenco Sonya,Adams Heather R.,Trundell Dylan,Coons Stephen Joel
Subject
Public Health, Environmental and Occupational Health,Health Policy
Reference21 articles.
1. Patient-reported outcome and observer-reported outcome assessment in rare disease clinical trials - an ISPOR COA Emerging Good Practices Task Force Report;Benjamin;Value Health,2017
2. Congress. Gov. H.R. 5238-Orphan Drug & the Orphan Drug Act, 97th Congress (1981-1982). Food and Drug Administration. https://www.congress.gov/bill/97th-congress/house-bill/5238https://www.fda.gov/industry/designating-orphan-product-drugs-and-biological-products/e-cfr-21-part-316-orphan-drug-orphan-drug-act-1983. Accessed March 30, 2021.
3. The European Union policy in the field of rare diseases;Moliner;Adv Exp Med Biol,2017
4. Estimating cumulative point prevalence of rare disease: analysis of the Orphanet database;Wakap;Eur J Hum Genet,2020
5. Rare disease terminology and definitions—a systematic global review: report of the ISPOR Rare Disease Special Interest Group;Richter;Value Health,2015
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献